US medical devices industry saw a drop of 11.01% in overall deal activity during September 2022, when compared with the last 12-month average, led by CVS Health’s $8bn acquisition of Signify Health, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 97 deals worth $10.3bn were announced in September 2022, compared with the 12-month average of 109 deals.
venture financing was the leading category in the month in terms of volume with 74 deals, which accounted for 76.3% of all deals.
In second place was M&A with 18 deals, followed by private equity with five transactions, respectively accounting for 18.6% and 5.2% of overall deal activity in the US technology industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $9.07bn, while venture financing and private equity deals totalled $760.5m and $488m, respectively.
US medical devices industry deals in September 2022: Top deals
The top five medical devices industry deals accounted for 91.6% of the overall value during September 2022.
The combined value of the top five medical devices deals stood at $9.44bn, against the overall value of $10.3bn recorded for the month.
The top five medical devices industry deals of September 2022 tracked by GlobalData were:
1) CVS Health’s $8bn acquisition deal with Signify Health
2) The $875m acquisition of Rx Savings Solutions by McKesson
3) Orbimed Advisors’s $250m private equity deal with Adaptive Biotechnologies
4) The $165m private equity of Theragun by HartBeat Ventures, North Castle Partners and Rx3 Ventures
5) Halma’s $154.02m acquisition deal with IZI Medical Products